Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
5 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 2 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Ticagrelor-aspirin combo improves graft patency rates 1 year post-CABG

Roshini Claire Anthony
11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

“In this trial, ticagrelor plus aspirin was superior to aspirin alone in maintaining saphenous vein graft patency for up to 1 year after elective CABG surgery in a general population that included a subgroup of patients with [acute coronary syndrome] and stable ischaemic heart disease,” said the researchers.

“Further study is needed to determine whether this significant benefit in graft patency translates into a meaningful improvement in clinical outcomes,” they said.

Five hundred patients (with 1,460 saphenous vein grafts; mean age 63.6 years, 18.2 percent female) from six hospitals in China received open-label ticagrelor (90 mg BID) plus aspirin (100 mg QD; n=168) or ticagrelor alone (90 mg BID; n=166) or aspirin alone (100 mg QD; n=166) for 1 year, with therapy initiated within 24 hours of undergoing elective CABG. Saphenous vein graft patency was assessed by means of computed tomographic angiography or coronary angiography.

One year post-CABG, saphenous vein graft patency rates were 88.7, 82.8, and 76.5 percent with ticagrelor plus aspirin, ticagrelor alone, and aspirin alone, respectively.

Saphenous vein graft patency rates were greater after 1 year among patients who received a combination of ticagrelor and aspirin compared with those who received aspirin only (difference, 12.2 percent, 95 percent confidence interval [CI], 5.2–19.2 percent; p<0.001). [JAMA 2018;319:1677-1686]

Conversely, there was little difference observed in saphenous vein graft patency rates between patients who received ticagrelor alone and aspirin alone (difference, 6.3 percent, 95 percent CI, -1.1 to 13.7 percent; p=0.10).

A post hoc analyses showed that saphenous vein graft nonocclusion rates at 1 year were 89.9, 86.1, and 80.6 percent in patients who received ticagrelor plus aspirin, ticagrelor alone, and aspirin alone, respectively, with a significantly improved rate among patients on ticagrelor plus aspirin vs aspirin alone (difference, 9.3 percent; p=0.006) but not for those on ticagrelor alone vs aspirin alone (difference, 5.4 percent; p=0.13).

The incidence of major adverse cardiac events was low overall (16 events). Five patients experienced major bleeding during the 1-year follow-up period, three in the ticagrelor plus aspirin and two in the ticagrelor alone groups, with one in each group experiencing CABG-related bleeding. Serious adverse events were experienced by three patients each in the ticagrelor plus aspirin and ticagrelor alone groups, and nine patients in the aspirin alone group.

The researchers acknowledged that the study may have been underpowered to detect if ticagrelor alone rendered a benefit. Additionally, as the study assessed the impact of dual antiplatelet therapy on saphenous vein graft patency, the results do not apply to arterial grafts, they said.

According to Professor John Alexander from the Duke Clinical Research Institute in Durham, North Carolina, US, these findings, while important, are not necessarily practice-changing.

“Fundamentally, angiographic vein graft patency is an imaging outcome and not a direct measure of how a patient feels, functions, or survives … [furthermore], not all vein graft failures result in a clinical event because the rate of vein graft failure is substantially higher than the rate of clinical events,” he commented in an editorial. [JAMA 2018;319:1661-1662]

“[I]t is premature to endorse the routine addition of ticagrelor to aspirin after CABG surgery,” he said, highlighting the importance of future research in the form of randomized trials in assessing the impact of ticagrelor on clinical outcomes. 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
5 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 2 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.